<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39395941</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2261</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>BMC cardiovascular disorders</Title><ISOAbbreviation>BMC Cardiovasc Disord</ISOAbbreviation></Journal><ArticleTitle>Baseline level of interleukin-6 is associated with the risk of acute coronary syndrome development in SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>550</StartPage><MedlinePgn>550</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">550</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12872-024-04234-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute coronary syndrome (ACS) is frequently reported in patients with coronavirus disease 2019 (COVID-19). Cytokine storm induced by interleukin-6 (IL-6) has been suggested to potentially cause myocardial injury in COVID-19. We investigated the association between baseline level of IL-6 and development of ACS in COVID-19 patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Demographic and clinical data of hospitalized COVID-19 patients from 2020 to 2022 were reviewed. Extracted data including patient characteristics, laboratory biomarkers, and systemic inflammation indexes in patients with or without ACS were reviewed and analyzed. Logistic regression models were applied to analyze predictors of ACS development and receiver-operating characteristic (ROC) curves were used to assess discriminatory power of IL-6 and other risk factors for predicting ACS development.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 1,753 COVID-19 patients, 37 cases experienced ACS and 159 patients without main COVID-19 complications were randomly selected as controls. ACS patients were older (p = 0.001) and suffered from more comorbidities including diabetes (43% vs. 18%, p = 0.001), hypertension (40.5% vs. 24.5%, p = 0.050), ischemic heart disease (49% vs. 9%, p = 0.001), and hyperlipidemia (19% vs. 5%, p = 0.010). Also, decreased level of consciousness (31.6% vs. 2.5%, p = 0.001), ICU admission (65% vs. 2%, p = 0.001), and mortality events (70% vs. 0.6%, p = 0.001) were more prevalent in the ACS group. Baseline levels of IL-6 (p = 0.001), D-dimer (p = 0.026), troponin (p = 0.001), blood urea nitrogen (p = 0.002), and creatinine (p = 0.008) were higher in ACS patients but erythrocyte sedimentation rate (p = 0.013), hemoglobin (p = 0.033), and red blood cells (p = 0.028) were lower compared with controls. Also, age (OR: 1.06, p = 0.019), IL-6 (OR: 1.44, p = 0.047), and cardiovascular disease (CVD) (OR: 3.66, p = 0.043) were associated with ACS development. The area under the curve (AUC) of IL-6 and combined predictors respectively was 0.661 (p = 0.002) and 0.829 (p = 0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">High IL-6 concentration at baseline is a strong predictor for ACS development in COVID-19 patients. Also, elderly and concurrent CVD are significantly associated with ACS development.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sedighi</LastName><ForeName>Mohsen</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0608-7840</Identifier><AffiliationInfo><Affiliation>Trauma and Injury Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahabi</LastName><ForeName>Mohammad Hasan</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Trauma and Injury Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akbarpour</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Trauma and Injury Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amanollahi</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1056-5438</Identifier><AffiliationInfo><Affiliation>Trauma and Injury Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavakoli</LastName><ForeName>Nader</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-5767-7771</Identifier><AffiliationInfo><Affiliation>Trauma and Injury Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammad Valipour</LastName><ForeName>Aydin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3681-6426</Identifier><AffiliationInfo><Affiliation>Trauma and Injury Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basir Ghafouri</LastName><ForeName>Hamed</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8792-7906</Identifier><AffiliationInfo><Affiliation>Trauma and Injury Research Center, Iran University of Medical Sciences, Tehran, Iran. Basirghafoori.h@iums.ac.ir.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Trauma and Injury Research Center, Rasoul Akram Hospital, Niayesh St, Satarkhan St, Tehran, 14456, Iran. Basirghafoori.h@iums.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cardiovasc Disord</MedlineTA><NlmUniqueID>100968539</NlmUniqueID><ISSNLinking>1471-2261</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054058" MajorTopicYN="Y">Acute Coronary Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="Y">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute coronary syndrome</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cytokine release syndrome</Keyword><Keyword MajorTopicYN="N">Interleukin-6</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>23</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39395941</ArticleId><ArticleId IdType="pmc">PMC11470654</ArticleId><ArticleId IdType="doi">10.1186/s12872-024-04234-x</ArticleId><ArticleId IdType="pii">10.1186/s12872-024-04234-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solano-López J, Zamorano JL, Sanz AP, Amat-Santos I, Sarnago F, Ibañes EG, et al. Risk factors for in-hospital mortality in patients with acute myocardial infarction during the COVID-19 outbreak. Revista Española de Cardiología. 2020;73(12):985 − 93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832619</ArticleId><ArticleId IdType="pubmed">32839121</ArticleId></ArticleIdList></Reference><Reference><Citation>Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA cardiology. 2020;5(7):831 − 40.</Citation><ArticleIdList><ArticleId IdType="pubmed">32219363</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanini GG, Montorfano M, Trabattoni D, Andreini D, Ferrante G, Ancona M, et al. ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. Circulation. 2020;141(25):2113-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7302062</ArticleId><ArticleId IdType="pubmed">32352306</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozbeyaz NB, Gokalp G, Algul E, Sahan HF, Aydinyilmaz F, Guliyev I, Kalkan K. H2FPEF Score and Contrast-Induced Nephropathy in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. Angiology. 2023;74(2):181–188.</Citation><ArticleIdList><ArticleId IdType="pubmed">35503102</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y, Gao P, Ran T, Qian H, Guo F, Chang L, et al. High inflammatory burden: a potential cause of myocardial injury in critically ill patients with COVID-19. Frontiers in cardiovascular medicine. 2020;7:128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7358346</ArticleId><ArticleId IdType="pubmed">32733921</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clinical immunology. 2020;214:108393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102614</ArticleId><ArticleId IdType="pubmed">32222466</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. Medecine et maladies infectieuses. 2020;50(4):382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7129451</ArticleId><ArticleId IdType="pubmed">32259560</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen N, Nguyen H, Ukoha C, Hoang L, Patel C, Ikram FG, et al., editors. Relation of interleukin-6 levels in COVID-19 patients with major adverse cardiac events. Baylor University Medical Center Proceedings; 2022: Taylor &amp; Francis.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8425472</ArticleId><ArticleId IdType="pubmed">34966215</ArticleId></ArticleIdList></Reference><Reference><Citation>Moccia F, Gerbino A, Lionetti V, Miragoli M, Munaron L, Pagliaro P, et al. COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches. Geroscience. 2020;42(4):1021-49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237344</ArticleId><ArticleId IdType="pubmed">32430627</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization WH. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, 28 January 2020. World Health Organization; 2020.</Citation></Reference><Reference><Citation>O’Connor RE, Al Ali AS, Brady WJ, Ghaemmaghami CA, Menon V, Welsford M, et al. Part 9: acute coronary syndromes: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132(18_suppl_2):S483-S500.</Citation><ArticleIdList><ArticleId IdType="pubmed">26472997</ArticleId></ArticleIdList></Reference><Reference><Citation>Fois AG, Paliogiannis P, Scano V, Cau S, Babudieri S, Perra R, et al. The Systemic Inflammation Index on Admission Predicts In-Hospital Mortality in COVID-19 Patients. Molecules. 2020;25(23).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7731255</ArticleId><ArticleId IdType="pubmed">33291581</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. Jama. 2022;327(7):662 − 75.</Citation><ArticleIdList><ArticleId IdType="pubmed">35166796</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical research in cardiology. 2020;109:531-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7087935</ArticleId><ArticleId IdType="pubmed">32161990</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito L, Cancro FP, Silverio A, Di Maio M, Iannece P, Damato A, et al. COVID-19 and acute coronary syndromes: from pathophysiology to clinical perspectives. Oxidative medicine and cellular longevity. 2021;2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8410438</ArticleId><ArticleId IdType="pubmed">34484561</ArticleId></ArticleIdList></Reference><Reference><Citation>Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648-55.</Citation><ArticleIdList><ArticleId IdType="pubmed">32200663</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet. 2020;395(10229):1033-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355–362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7201395</ArticleId><ArticleId IdType="pubmed">32376901</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Willey J. The interplay between inflammation and thrombosis in COVID-19: Mechanisms, therapeutic strategies, and challenges. Thromb Update. 2022;8:100117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9270234</ArticleId><ArticleId IdType="pubmed">38620713</ArticleId></ArticleIdList></Reference><Reference><Citation>Katritsis DG, Pantos J, Efstathopoulos E. Hemodynamic factors and atheromatic plaque rupture in the coronary arteries: from vulnerable plaque to vulnerable coronary segment. Coronary Artery Disease. 2007;18(3):229 − 37.</Citation><ArticleIdList><ArticleId IdType="pubmed">17429298</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier W, Altwegg LA, Corti R, Gay S, Hersberger M, Maly FE, Sütsch G, Roffi M, Neidhart M, Eberli FR, Tanner FC, Gobbi S, von Eckardstein A, Lüscher TF. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation. 2005;111(11):1355-61.</Citation><ArticleIdList><ArticleId IdType="pubmed">15753219</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nature reviews cardiology. 2020;17(5):259 − 60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095524</ArticleId><ArticleId IdType="pubmed">32139904</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydınyılmaz F, Özbeyaz NB, Guliyev İ, Algül E, Şahan HF, Kalkan K. Effect of Atherogenic Index of Plasma on Pre-Percutaneous Coronary Intervention Thrombolysis in Myocardial Infarction Flow in Patients With ST Elevation Myocardial Infarction. Angiology. 2023 Jul 3:33197231185204.</Citation><ArticleIdList><ArticleId IdType="pubmed">37399526</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaduganathan M, Vardeny O, Michel T, McMurray JJ, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. New England Journal of Medicine. 2020;382(17):1653-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121452</ArticleId><ArticleId IdType="pubmed">32227760</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy HM, Al-Gareeb AI, Al-Hussaniy HA, Al-Harcan NA, Alexiou A, Batiha GE. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality. Int Immunopharmacol. 2022; 104:108516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8733219</ArticleId><ArticleId IdType="pubmed">35032828</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>